MBX Biosciences Shares Surge on Positive Hypoparathyroidism Study Results
MBX Biosciences' stock more than doubled after promising trial results for its weekly thyroid treatment, canvuparatide, showing potential to address unmet needs in hypoparathyroidism management, with plans for Phase 3 in 2026.